These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 28630189)

  • 21. Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program.
    Farrell DJ; Liverman LC; Biedenbach DJ; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):415-20. PubMed ID: 21982563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
    Farrell DJ; Turner LL; Castanheira M; Jones RN
    Diagn Microbiol Infect Dis; 2012 Sep; 74(1):73-4. PubMed ID: 22819242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro activity of delafloxacin against bacterial isolates from osteoarticular and skin infections in Buenos Aires, Argentina].
    Nicola F; Azula N; Santoni G; Smayevsky J
    Rev Argent Microbiol; 2022; 54(2):114-119. PubMed ID: 34053809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
    Millar BC; McCaughan J; Rendall JC; Moore JE
    Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering.
    Bassetti M; Righi E; Pecori D; Tillotson G
    Future Microbiol; 2018 Aug; 13():1081-1094. PubMed ID: 29764190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delafloxacin for the treatment of respiratory and skin infections.
    Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
    Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Mohamed NM; Zakaria AS; Edward EA; Abdel-Bary A
    Pol J Microbiol; 2019; 68(1):59-69. PubMed ID: 31050254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2020 Aug; 80(12):1247-1258. PubMed ID: 32666425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
    Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
    Thabit AK; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci.
    Miller D; Chang JS; Flynn HW; Alfonso EC
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):339-44. PubMed ID: 23289847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization.
    Remy JM; Tow-Keogh CA; McConnell TS; Dalton JM; Devito JA
    J Antimicrob Chemother; 2012 Dec; 67(12):2814-20. PubMed ID: 22875850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of delafloxacin versus that of levofloxacin against anaerobic and microaerophilic isolates.
    Boyanova L; Yordanov D; Ouzounova-Raykova V; Markovska R; Marteva-Proevska Y; Mitov I
    Anaerobe; 2020 Apr; 62():102150. PubMed ID: 31987991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.
    Righi E; Carnelutti A; Vena A; Bassetti M
    Infect Drug Resist; 2018; 11():479-488. PubMed ID: 29670380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy.
    Van Bambeke F
    Future Microbiol; 2015; 10(7):1111-23. PubMed ID: 26119479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.
    Pullman J; Gardovskis J; Farley B; Sun E; Quintas M; Lawrence L; Ling R; Cammarata S;
    J Antimicrob Chemother; 2017 Dec; 72(12):3471-3480. PubMed ID: 29029278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.